<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Biotherapy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Biotherapy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский биотерапевтический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9784</issn><issn publication-format="electronic">1726-9792</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1348</article-id><article-id pub-id-type="doi">10.17650/1726-9784-2022-21-3-50-60</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Cyphetrylin effect on somatostatin receptors expression in transplantable Ca-755 mice tumor</article-title><trans-title-group xml:lang="ru"><trans-title>Влияние цифетрилина на экспрессию рецепторов к соматостатину в перевиваемой опухоли Са-755 мышей</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4309-6722</contrib-id><name-alternatives><name xml:lang="en"><surname>Kiseleva</surname><given-names>M. P.</given-names></name><name xml:lang="ru"><surname>Киселева</surname><given-names>М. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Marina Petrovna Kiseleva</p><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>Марина Петровна Киселева</p><p>115522 Москва, Каширское шоссе, 24</p></bio><email>marina-kiselyova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4613-4584</contrib-id><name-alternatives><name xml:lang="en"><surname>Borisova</surname><given-names>L. M.</given-names></name><name xml:lang="ru"><surname>Борисова</surname><given-names>Л. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4550-2069</contrib-id><name-alternatives><name xml:lang="en"><surname>Delektorskaya</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Делекторская</surname><given-names>В. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3034-750X</contrib-id><name-alternatives><name xml:lang="en"><surname>Shprakh</surname><given-names>Z. S.</given-names></name><name xml:lang="ru"><surname>Шпрах</surname><given-names>З. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0298-3894</contrib-id><name-alternatives><name xml:lang="en"><surname>Ustinkina</surname><given-names>S. V.</given-names></name><name xml:lang="ru"><surname>Устинкина</surname><given-names>С. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kubasova</surname><given-names>I. Yu.</given-names></name><name xml:lang="ru"><surname>Кубасова</surname><given-names>И. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-10-31" publication-format="electronic"><day>31</day><month>10</month><year>2022</year></pub-date><volume>21</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>50</fpage><lpage>60</lpage><history><date date-type="received" iso-8601-date="2022-10-31"><day>31</day><month>10</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-10-31"><day>31</day><month>10</month><year>2022</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://bioterapevt.abvpress.ru/jour/article/view/1348">https://bioterapevt.abvpress.ru/jour/article/view/1348</self-uri><abstract xml:lang="en"><p><bold>Background.</bold> Expression evaluation of somatostatin receptors (SSTRs) in tumor cells is necessary for the reasonable use of therapy directed at such receptors.<bold>Aim.</bold> The affinity determination of the original analogue of somatostatin cyphetrylin for SSTRs of transplanted mice mammary adenocarcinoma Ca-755.<bold>Materials and methods.</bold> Cyphetrylin was synthesized in the Chemical Synthesis Laboratory of the Research Institute of Experimental Diagnostics and Therapy of Tumors, N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia. Cyphetrylin in tablet form was administered orally at a therapeutic dose of 10 mg/kg for 7 days to female F1 (C57Bl/6 × DBA/2) tumor-grafted Ca-755 mice. Animals of the control group were not administreted with сyphetrylin. Tumor tissue samples were obtained from animals on the 9th and 14th days after Ca-755 transplantation and sent for immunohistochemical study, which was performed on serial paraffin sections by the immunoperoxidase method using primary antibodies to various types of SSTRs.<bold>Results</bold>. The high frequency of positive expression of SSTR1, SSTR2, and SSTR5 (in 80, 100 and 100 % of tumor samples, respectively) was shown in tumor samples of the control group animals. As a result of cyphetrylin introduction in tumor samples obtained on the 9th day after Ca-755 inoculation, a change in the tumor receptor status was found towards a decrease in the level of expression of SSTR2 (80 % of samples) and SSTR5 (80 % of samples); SSTR1 expression did not change (80 % of samples). Compared to the controlled, in tumor samples after cyphetrylin administration, obtained on day 14 from Ca-755 transplantation, a decrease in the expression level of SSTR2 (80 % of samples), SSTR1 and SSTR5 (60 % of samples for SSTR each type) was noted, due to cyphetrylin binding to SSTRs of tumor cells. The receptors SSTR3 and SSTR4 did not show a high level of expression in the studied Ca-755 tumor samples.Immunohistochemical staining of Ca-755 cells with antibodies to SSTRs showed a tendency to reduction of antigen-positive cells number from 15–50 % in control to 10–40 % on day 9 after Ca-755 transplantation and 10–30 % on day 14 after Ca-755 transplantation.<bold>Conclusion.</bold> The data obtained indicates the presence in mice transplanted mammary adenocarcinoma Ca-755 of SSTR1, SSTR2 and SSTR5 high level expression due to the binding to which the direct cyphetrylin antitumor effect is realized.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение</bold>. Оценка экспрессии рецепторов к соматостатину (somatostatin receptors, SSTRs) в опухолевых клетках необходима для обоснованного применения направленной на такие рецепторы терапии.<bold>Цель исследования</bold> – определение сродства оригинального аналога соматостатина цифетрилина к SSTRs перевиваемой аденокарциномы молочной железы Са-755 мышей.<bold>Материалы и методы</bold>. Цифетрилин синтезирован в лаборатории химического синтеза Научно-исследовательского института экспериментальной диагностики и терапии опухолей ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России. Цифетрилин в лекарственной форме в виде таблеток вводили перорально в  терапевтической дозе 10 мг/кг в  течение 7 дней мышам-самкам F1 (C57Bl/6 × DBA/2) с привитой опухолью Ca-755. Животным контрольной группы цифетрилин не вводили. Образцы опухолевой ткани получали от животных на 9-й и 14-й дни после трансплантации Са-755 и направляли на иммуногистохимическое исследование, которое проводили на серийных парафиновых срезах иммунопероксидазным методом с использованием первичных антител к различным типам SSTRs.<bold>Результаты.</bold> В опухолевых образцах от животных контрольной группы показана высокая частота встречаемости положительной экспрессии SSTR1, SSTR2 и SSTR5 (в 80, 100 и 100 % опухолевых образцов соответственно). В результате введения цифетрилина в опухолевых образцах, полученных на 9-й день после перевивки Ca-755, обнаружено изменение рецепторного статуса опухоли в сторону уменьшения уровня экспрессии SSTR2 (80 % образцов) и SSTR5 (60 % образцов); экспрессия SSTR1 не изменилась (80 % образцов). При сравнении с контролем в опухолевых образцах от животных, которым вводили цифетрилин, полученных на 14-й день после трансплантации Са-755, отмечено понижение уровня экспрессии SSTR2 (80 % образцов), SSTR1 и SSTR5 (по 60 % образцов соответственно) вследствие связывания цифетрилина с SSTRs опухолевых клеток. SSTR3 и SSTR4 не демонстрировали высокого уровня положительной экспрессии в исследованных образцах опухоли Са-755. При иммуногистохимическом окрашивании клеток Са-755 антителами к SSTRs зафиксирована тенденция к снижению количества антигенпозитивных клеток с 15–50 % в контроле до 10–40 % на 9-й день после перевивки Са-755 и до 10–30 % на 14-й день после перевивки Са-755.<bold>Заключение.</bold> Полученные данные свидетельствуют о  наличии в  перевиваемой аденокарциноме молочной железы Са-755 мышей высокого уровня экспрессии SSTR1, SSTR2 и SSTR5, за счет связывания с которыми реализуется прямое противоопухолевое действие цифетрилина.</p></trans-abstract><kwd-group xml:lang="en"><kwd>somatostatin analogue cyphetrylin</kwd><kwd>somatostatin receptors</kwd><kwd>transplantable mouse tumors</kwd><kwd>immunohistochemical analysis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>аналог соматостатина цифетрилин</kwd><kwd>рецепторы к соматостатину</kwd><kwd>перевиваемые опухоли мышей</kwd><kwd>иммуногистохимический анализ</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The study was performed in the framework research work “Pharmaceutical development and preclinical studies of original innovative drugs with an improved safety profile for the treatment of malignant neoplasms” (№ АААА-А20-120031190013-9, 2020–2022).</funding-statement><funding-statement xml:lang="ru">Исследование проведено в рамках государственного задания по теме «Фармацевтическая разработка и доклинические исследования оригинальных инновационных лекарственных средств с улучшенным профилем безопасности для лечения злокачественных новообразований» (№ АААА-А20-120031190013-9, 2020–2022 гг.).</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Barbieri F., Bajetto A., Pattarozzi A. et al. Peptide receptor targeting in cancer: the somatostatin paradigm. Int J Pept 2013;2013:926295. DOI: 10.1155/2013/926295</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Kumar U., Grant M. Somatostatin and somatostatin receptors. In: Cellular peptide hormone synthesis and secretory pathways. Ed. by J.F. Rehfeld, J.R. Bundgaard. Berlin: Springer, 2010. Pp.: 97–120. DOI: 10.1007/400_2009_29</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Günther T., Tulipano G., Dournaud P. et al. International Union of Basic and Clinical Pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature. Pharmacol Rev 2018;70(4):763–835. DOI: 10.1124/pr.117.015388</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Klomp M.J., Dalm S.U., de Jong M. et al. Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer. Rev Endocr Metab Disord 2021;22(3):495–510. DOI: 10.1007/s11154-020-09607-z</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Bartsch D.K., Scherübl H. Neuroendocrine tumors of the gastrointestinal tract. Visc Med 2017;33(5):321–2. DOI: 10.1159/000481766</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Klöppel G. Neuroendocrine neoplasms: dichotomy, origin and classifications. Visc Med 2017;33(5):324–30. DOI: 10.1159/000481390</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Mafficini A., Scarpa A. Genetics and epigenetics of gastroenteropancreatic neuroendocrine neoplasms. Endocr Rev 2019;40(2):506–36. DOI: 10.1210/er.2018-00160</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Vinik A.I., Chaya C. Clinical presentation and diagnosis of neuroendocrine tumors. Hematol Oncol Clin North Am 2016;30(1):21–48. DOI: 10.1016/j.hoc.2015.08.006</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Cakir M., Dworakowska D., Grossman A. Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1 – molecular pathways. J Cell Mol Med 2010;14(11):2570–84. DOI: 10.1111/j.1582-4934.2010.01125.x</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Watanabe H., Fujishima F., Komoto I. et al. Somatostatin receptor 2 expression profiles and their correlation with the efficacy of somatostatin analogues in gastrointestinal neuroendocrine tumors. Cancers (Basel) 2022;14(3):775. DOI: 10.3390/cancers1403077</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Hankus J., Tomaszewska R. Neuroendocrine neoplasms and somatostatin receptor subtypes expression. Nucl Med Rev Cent East Eur 2016;19(2):111–7. DOI: 10.5603/NMR.2016.0022</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Hofland J., Kaltsas G., de Herder W.W. Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms. Endocr Rev 2020;41(2):371–403. DOI: 10.1210/endrev/bnz004</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Hu Y., Ye Z., Wang F. et al. Role of somatostatin receptor in pancreatic neuroendocrine tumor development, diagnosis and therapy. Front Endocrinol (Lausanne) 2021;12:679000. DOI: 10.3389/fendo.2021.679000</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Hallet J., Law C.H.L., Cukier M. et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 2015;121(4):589–97. DOI: 10.1002/cncr.29099</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Vesterinen T., Leijon H., Mustonen H. et al. Somatostatin receptor expression is associated with metastasis and patient outcome in pulmonary carcinoid tumors. J Clin Endocrinol Metab 2019;104(6):2083–93. DOI: 10.1210/jc.2018-01931</mixed-citation></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Morgunov L.Yu. Somatostatin analogs in neuroendocrine tumors treatment. RMJ = RMJ 2019;27(6):10–14. Available at: https://www.rmj.ru/articles/onkologiya/Analogi_somatostatina_v_lechenii_neyroendokrinnyh_opuholey/#ixzz75J4HQaUz. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Моргунов Л.Ю. Аналоги соматостатина в лечении нейроэндокринных опухолей. РМЖ 2019;27(6):10–14. Доступно по: https://www.rmj.ru/articles/onkologiya/Analogi_somatostatina_v_lechenii_neyroendokrinnyh_opuholey/#ixzz75J4HQaUz.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><mixed-citation>Pryyma A., Matinkhoo K., Jia Bu Y. et al. Synthesis and preliminary evaluation of octreotate conjugates of bioactive synthetic amatoxins for targeting somatostatin receptor (sstr2) expressing cells. RSC Chem Biol 2022;3(1):69–78. DOI: 10.1039/d1cb00036e</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Wang Y., Wang W., Jin K. et al. Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors. Oncol Lett 2017;13(3):1165–74. DOI: 10.3892/ol.2017.5591</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Labadzhyan A., Nachtigall L.B., Fleseriu M. et al. Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results. Pituitary 2021;24(6):943–53. DOI: 10.1007/s11102-021-01163-2</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Gulde S., Wiedemann T., Schillmaier M. et al. Gender-specific efficacy revealed by head-to-head comparison of pasireotide and octreotide in a representative in vivo model of nonfunctioning pituitary tumors. Cancers (Basel) 2021;13(12):3097. DOI: 10.3390/cancers13123097</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Pedroncelli A.M. Medical treatment of Cushing’s disease: somatostatin analogues and pasireotide. Neuroendocrinology 2010;92(Suppl 1):120–4. DOI: 10.1159/000314352</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Streit L., Moog S., Hugel S. et al. Somatostatin analogue pasireotide (SOM230) inhibits catecholamine secretion in human pheochromocytoma cells. Cancer Lett 2022;524:232–44. DOI: 10.1016/j.canlet.2021.10.009</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Schmid H.A. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 2008;286(1–2):69–74. DOI: 10.1016/j.mce.2007.09.006</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Gut P., Czarnywojtek A., Sawicka-Gutaj N. et al. Evaluation of the expression of somatostatin receptors by immunohistochemistry in neuroendocrine tumors of the small intestine. Pol J Pathol 2020;71(1):30–7. DOI: 10.5114/pjp.2020.95413</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Popa O., Taban S.M., Pantea S. et al. The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5. Exp Ther Med 2021;22(4):1179. DOI: 10.3892/etm.2021.10613</mixed-citation></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Kolomeytseva A.A., Delektorskaya V.V., Orel N.F. et al. Somatostatin receptors as potential therapeutic targets in the treatment of advanced adrenocortical cancer. A case report. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology 2018;17(2):111–7. (In Russ.). DOI: 10.21294/1814-4861-2018-17-2-111-117</mixed-citation><mixed-citation xml:lang="ru">Коломейцева А.А., Делекторская В.В., Орел Н.Ф. и др. Рецепторы соматостатина как потенциальная терапевтическая мишень в лечении распространенного адренокортикального рака. Клинический случай. Сибирский онкологический журнал 2018;17(2):111–7. DOI: 10.21294/1814-4861-2018-17-2-111-117</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Gurevich L.E., Korsakova N.A., Voronkova I.A. et al. Immunohistochemical determination of expression of somatostatin receptors types 1, 2А, 3 and 5 in neuroendocrine tumors of various localization and grade. Almanah klinicheskoy meditsiny = Almanac of Clinical Medicine 2016;44(4):378–90. (In Russ.). DOI: 10.18786/2072-0505-2016-44-4-378-390</mixed-citation><mixed-citation xml:lang="ru">Гуревич Л.Е., Корсакова Н.А., Воронкова И.А. и др. Иммуногистохимическое определение экспрессии рецепторов к соматостатину 1, 2А, 3 и 5-го типов в нейроэндокринных опухолях различной локализации и степени злокачественности. Альманах клинической медицины 2016;44(4):378–90. DOI: 10.18786/2072-0505-2016-44-4-378-390</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><mixed-citation>Franck S.E., Gatto F., van der Lely A.J. et al. Somatostatin receptor expression in GH-secreting pituitary adenomas treated with long-acting somatostatin analogues in combination with pegvisomant. Neuroendocrinology 2017;105(1):44–53. DOI: 10.1159/000448429</mixed-citation></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Balaev A.N., Osipov V.N., Fedorov V.E. et al. Synthesis and cytotoxic activity for hypothalamic hormone somatostatine analogs. Rossijskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2012;11(4):47–53. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Балаев А.Н., Осипов В.Н., Федоров В.Е. и др. Синтез и изучение цитотоксической активности аналогов гипоталамического гормона соматостатина. Российский биотерапевтический журнал 2012;11(4):47–53.</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Borisova L.M., Kiseleva M.P., Osipov V.N. et al. Cyphetrylin cytotoxic analogues (report II). Rossijskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2017;2(16):23–9. (In Russ.). DOI: 10.17650/1726-9784-2017-16-2-23-29</mixed-citation><mixed-citation xml:lang="ru">Борисова Л.М., Киселева М.П., Осипов В.Н. и др. Цитотоксические аналоги цифетрилина (сообщение II). Российский биотерапевтический журнал 2017;2(16):23–9. DOI: 10.17650/1726-9784-2017-16-2-23-29</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">Shprakh Z.S., Yartseva I.V., Ignat’eva E.V. et al. Synthesis and chemico-pharmaceutical characterization of somatostatin analog with antitumor activity. Himiko-farmatsevticheskiy jurnal = Pharmaceutical Chemistry Journal 2014;48(3):19–22 (In Russ.). DOI: 10.30906/0023-1134-2014-48-3-19-22</mixed-citation><mixed-citation xml:lang="ru">Шпрах З.С., Ярцева И.В., Игнатьева Е.В. и др. Синтез и химико-фармацевтические характеристики аналога соматостатина, обладающего противоопухолевой активностью. Химико-фармацевтический журнал 2014;48(3):19–22. DOI: 10.30906/0023-1134-2014-48-3-19-22</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">Experimental evaluation of antitumor drugs in the USSR and the USA. Ed. by Z.P. Sofina, A.B. Syrkin, A. Goldin, A. Klein. Moscow: Meditsina, 1980. 296 p. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Экспериментальная оценка противоопухолевых препаратов в СССР и США. Под ред. З.П. Софьина, А.Б. Сыркина, A. Голдина, И. Кляйн. М.: Медицина, 1980. 296 c.</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><mixed-citation>Volante M., Brizzi M.P., Faggiano A. et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 2007;20(11):1172–82. DOI: 10.1038/modpathol. 3800954</mixed-citation></ref></ref-list></back></article>
